BCAX
Bicara Therapeutics Inc.Company Information
- Company Name
- Bicara Therapeutics Inc.
- CIK
- CIK0002023658
- Category
- <br>Emerging growth company
- Ticker: Exchange
- BCAX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BCAX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-02-26
- Last sale
- 2026-09-08
- Shares purchased (TTM)
- 300,000
- Shares sold (TTM)
- 534,838
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 61,802,273
- Shares outstanding
- 67,925,963
- Ownership
- 90.98%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -2.48%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | 1 | 6 | 6 | 1 | -0 | 2 | 4 | 2 | ||||||
| Related Party | 1 | 6 | 6 | 1 | -0 | 2 | 4 | 2 | ||||||
Assets Current | ||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 97 | 323 | 97 | 172 | 437 | 462 | 490 | 521 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 5 | 7 | 7 | 8 | 9 | 13 | 1 | ||||||
| Short Term Investments | - | - | 318 | 118 | - | - | 0 | - | ||||||
| Marketable Securities Current | 401 | 216 | - | - | - | - | - | - | ||||||
| Assets Current | 504 | 545 | 422 | 297 | 444 | 471 | 503 | 522 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 0 | ||||||
| Long Term Investments | - | - | - | 117 | - | - | - | - | ||||||
| Other Assets Noncurrent | 7 | 7 | 7 | 8 | 7 | 7 | 7 | 2 | ||||||
| Assets | 512 | 554 | 431 | 425 | 454 | 478 | 510 | 524 | ||||||
Liabilities Current | ||||||||||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Accrued Liabilities Current | - | - | - | - | - | - | 13 | - | ||||||
| Liabilities Current | 43 | 39 | 29 | 21 | 17 | 19 | 18 | 14 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Liabilities | 43 | 40 | 30 | 22 | 18 | 19 | 18 | 15 | ||||||
Stockholders Equity | ||||||||||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 940 | 929 | 760 | 724 | 720 | 717 | 713 | 710 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 0 | 0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | -0 | - | - | 0 | - | ||||||
| Retained Earnings Accumulated Deficit | -471 | -415 | -359 | -322 | -285 | -258 | -221 | -200 | ||||||
| Stockholders Equity | 469 | 514 | 401 | 403 | 435 | 459 | 492 | 510 | ||||||
| Liabilities And Stockholders Equity | 512 | 554 | 431 | 425 | 454 | 478 | 510 | 524 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Seed Series Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Series B Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | 0 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | 0 | ||||||
| Series C Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Issued | 66 | 66 | 57 | 55 | 55 | 55 | 54 | 54 | ||||||
| Shares Outstanding | 66 | 66 | 57 | 55 | 55 | 55 | 54 | 54 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBicara Therapeutics Inc. (BCAX) — SEC Financial Statements & Analysis
Bicara Therapeutics Inc. (BCAX) is a pharmaceutical preparations company, incorporated in DE. Bicara Therapeutics Inc. trades on Nasdaq as: BCAX. Bicara Therapeutics Inc. (BCAX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Bicara Therapeutics Inc. carries a market cap of $2.02B, a P/E ratio of -10.88x, a P/B ratio of 4.30x, an enterprise value of $1.92B, and an EV/EBITDA multiple of -9.51x. On profitability, it posts a Return on Equity (ROE) of -41.01%, a Return on Assets (ROA) of -38.38%, and a Return on Invested Capital (ROIC) of -108.84%. Per share, it reports EPS of $-2.73, diluted EPS of $-2.73, free cash flow per share of $-1.99, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 40.18% year-over-year and EPS growth of 12.56% year-over-year. On the balance sheet, it maintains a current ratio of 11.59x, a quick ratio of 11.44x, working capital of $460.35M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-135.25M (TTM), and net debt of $-96.60M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.02B
- P/E TTM
- -10.88x
- EPS TTM
- $-2.73
- P/B TTM
- 4.30x
- ROE TTM
- -41.01%
- ROA TTM
- -38.38%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-135.25M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Bicara Therapeutics Inc. in?
Bicara Therapeutics Inc. (BCAX) operates in the Pharmaceutical Preparations industry.
What exchange does BCAX trade on?
Bicara Therapeutics Inc. (BCAX) trades on the Nasdaq.
Where is Bicara Therapeutics Inc. incorporated?
Bicara Therapeutics Inc. is incorporated in DE.
When was Bicara Therapeutics Inc. (BCAX)'s most recent SEC filing?
Bicara Therapeutics Inc. (BCAX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is BCAX's market cap?
Bicara Therapeutics Inc. (BCAX) has a market capitalization of $2.02B as of 2026-06-30.
What is BCAX's EPS (earnings per share)?
Bicara Therapeutics Inc. (BCAX)'s trailing twelve month EPS is $-2.73 as of 2026-06-30.
What is BCAX's ROE (return on equity)?
Bicara Therapeutics Inc. (BCAX)'s trailing twelve month Return on Equity (ROE) is -41.01% as of 2026-06-30.
What is BCAX's ROA (return on assets)?
Bicara Therapeutics Inc. (BCAX)'s trailing twelve month Return on Assets (ROA) is -38.38% as of 2026-06-30.
What is BCAX's ROIC (return on invested capital)?
Bicara Therapeutics Inc. (BCAX)'s trailing twelve month Return on Invested Capital (ROIC) is -108.84% as of 2026-06-30.
What is BCAX's EV/EBITDA?
Bicara Therapeutics Inc. (BCAX)'s trailing twelve month EV/EBITDA is -9.51x as of 2026-06-30.